middle.news
InhaleRx Unveils Oral Esketamine Therapy and Rebrands to Nexalis Therapeutics
10:42am on Wednesday 10th of December, 2025 AEDT
•
Healthcare
Read Story
InhaleRx Unveils Oral Esketamine Therapy and Rebrands to Nexalis Therapeutics
10:42am on Wednesday 10th of December, 2025 AEDT
Key Points
Three fully funded drug candidates targeting pain and mental health
New oral therapy SRX-25 for treatment-resistant depression entering Phase 1
IRX-211 and IRX-616a progressing in Phase 2 and Phase 1 trials respectively
Company to rebrand as Nexalis Therapeutics to reflect expanded portfolio
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Inhalerx (ASX:IRX)
OPEN ARTICLE